Radiation associated coronary occlusion: Overlooked as trastuzumab-induced cardiomyopathy - Open Journal of Internal Medicine

OJIM > Vol.3 No.1, March 2013

Radiation associated coronary occlusion: Overlooked as trastuzumab-induced cardiomyopathy ()

HTML XML

Download as PDF (Size: 177KB) PP. 1-2

DOI: 10.4236/ojim.2013.31001 3,085 Downloads 4,906 Views

Author(s)

Ugur Turk, Veysel Yavuz, Nurullah Cetin

Affiliation(s)

Department of Cardiology, Celal Bayar University, Manisa, Turkey.
Department of Cardiology, Central Hospital, Izmir, Turkey.

ABSTRACT

Trastuzumab is an agent used for receptor-positive breast cancer. Up to a third of patients treated with trastuzumab might develop cardiomyopathy. Many patients with breast cancer have taken pre- or co-administration of mediastinal radiotherapy. Both of treatment modalities have toxic effects on myocardium. It may result with diagnostic confusion between radiation-induced CAD (riCAD) and trastuzumab cardiomyopathy in the case with dilated cardiomyopathy. TTE may offer clues of differential diagnosis.

KEYWORDS

Cardiomyopathy; Trastuzumab; Radiation

Share and Cite:

Turk, U. , Yavuz, V. and Cetin, N. (2013) Radiation associated coronary occlusion: Overlooked as trastuzumab-induced cardiomyopathy. Open Journal of Internal Medicine, 3, 1-2. doi: 10.4236/ojim.2013.31001.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies